The IMA Group Marks 35 Years of Growth from Medical Evaluations to Clinical Research Network
The IMA Group has evolved from medical screening services into a national clinical research organization with 150 locations, demonstrating how healthcare companies can successfully expand while maintaining quality standards.
The IMA Group celebrates its 35th anniversary this year, marking a significant transformation from its origins in medical screenings and psychological evaluations to becoming a national organization with more than 150 locations and a rapidly expanding clinical research network. Under the leadership of President and CEO Mark Weinberger for the past 14 years, the company has maintained its longevity through what Weinberger describes as three essential pillars: great people, commitment to quality, and willingness to adapt and evolve.
IMA operates as a national leader in outsourced medical, psychological, and ancillary evaluations and screenings, serving government agencies, insurers, third-party administrators, and employers. The company provides psychological and medical assessments for public safety programs evaluating police officers, firefighters, and other essential personnel. For workers' compensation, disability, injury, or auto liability claims, IMA supports insurers and employers through independent medical exams, medical file reviews, case management, and rehabilitation guidance.
The company's expansion into clinical research represents a strategic evolution that began in 2018 with a growth strategy combining organic investment with targeted acquisitions. IMA has acquired 19 businesses, with 10 now integrated into its research division. This expansion was a natural progression, as clinical research and evaluation share many characteristics: precise data collection, regulatory discipline, and patient-centered execution. The company's clinical research network now includes 19 dedicated research sites conducting Phase II-IV clinical trials across locations from New York and Chicago to Albuquerque, New Mexico, and Hickory, North Carolina.
Weinberger emphasizes that technology plays a crucial role in IMA's operations, with the company deploying AI tools and predictive modeling to optimize trial recruitment, match patients efficiently, and analyze data with greater precision. The organization supports telehealth visits, mobile data capture, remote monitoring, and home visits designed to reduce barriers and improve convenience for patients. For evaluations, IMA relies on secure scheduling dashboards, portals, and real-time tracking to ensure transparency and timely reporting.
Looking ahead, IMA sees significant growth potential across both evaluation and research platforms. In clinical research, the company is focusing on therapeutic areas like central nervous system disorders, sleep conditions, and metabolic diseases, where clinical gaps remain significant. The organization is also expanding its work in GLP-1 studies, which continue to grow rapidly. Beyond therapeutic areas, IMA is scaling its workers' compensation, liability, auto/no-fault, and occupational health evaluations in response to evolving regulations and workforce needs. The company is piloting new models in hybrid and decentralized trials, advanced biomarkers, and real-world evidence integration.
Weinberger notes that IMA's diverse clinic network provides substantial benefits for both patients and research sponsors. The company's 150 clinics across the country create infrastructure capable of recruiting diverse, representative patient populations more quickly while delivering high-quality data. For patients, this means access to clinical research opportunities and evaluation services in their local communities without extensive travel requirements. The organization has further expanded its reach through satellite and outreach sites, recognizing that local accessibility builds trust and engagement essential for both accurate evaluations and successful clinical trials.